Outlook Therapeutics: The Treatment of Neovascular AMD. Introducing Bevacizumab Gamma – the First Approved Ophthalmic Formulation of Bevacizumab
Location: 212
Date & Time: Friday, 20 September, 17:45 - 18:45 CEST
Chairperson(s): F. Bandello, ITALY
Speakers:
Presentations:
F. Bandello ITALY
17:45 Evidence-Based Use of Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration
T. Jackson UK
18:05 Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration – the challenges to date
J. Kissner USA
18:25 Efficacy and Safety of Bevacizumab Gamma (LytenavaTM) in the Treatment of Neovascular Age-Related Macular Degeneration
This is a promotional symposium for HCPs only. Presentations and materials disclosed during the event are subject to Intellectual Property Rights. Total or partial reproduction or use of this content requires prior AbbVie authorization. Furthermore, in order to comply with the regulations regarding the promotion of medicines, we ask you not to share its contents on your social networks. Please do not distribute in media, or communication channels aimed at the general public.